Literature DB >> 20809502

Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma.

Jonathan R Fromm1.   

Abstract

Although the diagnosis of classical Hodgkin lymphoma (CHL) is traditionally made morphologically in tissue sections, it is now possible to diagnose CHL by flow cytometry (FC). In an effort to identify additional antigens on Hodgkin and Reed-Sternberg (HRS) cells that might be useful for immunophenotyping this lymphoma by FC, we examined the expression of CD123 (α chain of the IL-3R) on HRS cells and compared this with the expression of CD123 in other lymph node samples (372 tissue specimens, including 98 reactive and 274 neoplastic cases), using a nine-color FC reagent combination including anti-CD123. CD123 was found to be expressed on the majority of HRS cell populations (59% of 59 CHL lymph nodes examined), rarely on B-cell non-Hodgkin lymphomas (NHLs) (3 of 3 hairy cell leukemia cases, 3 of 29 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) cases, 1 of 55 large B-cell lymphoma cases, but not on 95 other B-cell NHL examined), and in none of the 16 T-cell NHL cases examined. In reactive lymph nodes, CD123 expression was largely limited to plasmacytoid dendritic cells and rare histiocyte populations that can readily be distinguished from HRS populations. As the expression of this antigen is shown to be relatively limited in B- and T-NHL and in reactive lymph node populations, assessment of CD123 expression is useful for supporting the FC diagnosis of CHL.
Copyright © 2010 International Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809502     DOI: 10.1002/cyto.b.20561

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  12 in total

1.  Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery.

Authors:  Timothy E Andrews; Dan Wang; Daniel A Harki
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

Review 2.  Targeting Immune System Alterations in Hodgkin Lymphoma.

Authors:  Natalie S Grover; Barbara Savoldo
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

3.  Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.

Authors:  Girish Venkataraman; Christine Aguhar; Robert J Kreitman; Constance M Yuan; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2011-10       Impact factor: 2.493

4.  Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Authors:  Marco Ruella; Michael Klichinsky; Saad S Kenderian; Olga Shestova; Amy Ziober; Daniel O Kraft; Michael Feldman; Mariusz A Wasik; Carl H June; Saar Gill
Journal:  Cancer Discov       Date:  2017-06-02       Impact factor: 39.397

5.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

6.  Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.

Authors:  Ibrahim Aldoss; Mary Clark; Joo Y Song; Vinod Pullarkat
Journal:  Hum Vaccin Immunother       Date:  2020-07-21       Impact factor: 3.452

7.  Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma.

Authors:  Meret Henry; Steven Buck; Süreyya Savaşan
Journal:  Pediatr Blood Cancer       Date:  2018-07-15       Impact factor: 3.167

Review 8.  Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors.

Authors:  Natalie S Grover; Nicholas Tschernia; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

9.  Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.

Authors:  Simon Loff; Josephine Dietrich; Jan-Erik Meyer; Julia Riewaldt; Johannes Spehr; Malte von Bonin; Cordula Gründer; Mridula Swayampakula; Kristin Franke; Anja Feldmann; Michael Bachmann; Gerhard Ehninger; Armin Ehninger; Marc Cartellieri
Journal:  Mol Ther Oncolytics       Date:  2020-04-29       Impact factor: 7.200

10.  Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.

Authors:  Daniel Ernst; Brent A Williams; Xing-Hua Wang; Nara Yoon; Kyung-Phil Kim; Jodi Chiu; Zhi Juan Luo; Karin G Hermans; Joerg Krueger; Armand Keating
Journal:  Blood Cancer J       Date:  2019-01-15       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.